On August 17, 2011, after a decade characterized by a dearth of new therapies for advanced melanoma, vemurafenib was approved as the first targeted therapy for unresectable or metastatic melanoma.1 Vemurafenib was designed to target only BRAF V600E-positive melanomas, thereby increasing efficacy and reducing the off-target systemic toxic effects seen in prior melanoma treatments, such as high-dose interferon. This historic breakthrough marked a major milestone in precision oncology, the practice of selecting a treatment based on the genetics and molecular characteristics of an individual patient’s tumor, and opened the door to a new era of targeted therapy for dermatologic conditions.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wang JY, Sarin KY. Dermatology Advances Into an Era of Precision Medicine. JAMA Dermatol. Published online June 02, 2021. doi:10.1001/jamadermatol.2021.0024
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: